Zemany et al. explored whether decreasing TTR levels with antisense oligonucleotides (ASOs) improves glucose metabolism and insulin sensitivity in obese individuals and reported that TTR-ASO treatment of mice with genetic or diet-induced obesity resulted in an 80–95% decrease in the circulating levels of TTR and RBP4 and improved insulin sensitivity in ob/ob mice and high-fat diet-fed mice as early as 2 weeks after treatment [123]. Here, TTR is linked to obesity due to melanocortin 4 receptor deficiency.